Arixtra 2.5 MG/0.5 ML Solution For Injection View larger

Arixtra 2.5 MG/0.5 ML Solution For Injection


New product



More details

2000 Items


Volume discounts

QuantityDiscountYou Save
2 5% Up to $9.80
3 10% Up to $29.40
4 15% Up to $58.80
5 20% Up to $98.00

More info

ARIXTRA 2.5 mg/0.5 ml solution for injection For subcutaneous or intravenous administration.

Active ingredient
Each 0.5 ml solution contains 2.5 mg fondaparinax.

Sodium chloride, water for injections and hydrochloric acid or sodium hydroxide

1. How to use ARIXTRA?

Prevention of clot formation:

Orthopedic and abdominal surgery: The recommended dose of ARIXTRA is 2.5 mg administered once daily by subcutaneous injection after surgery.

The first dose should not be given earlier than 6 hours after the end of the surgical procedure. Treatment should be continued for at least 5-9 days after surgery, until the risk of clotting is eliminated and the patient is usually able to stand up and walk.

In patients who have undergone hip fracture surgery, extended treatment with ARIXTRA for up to an additional 24 days should be considered.
In the treatment of narrowing / occlusion of the vessels feeding the heart or heart attack:

The recommended dose of ARIXTRA is 2.5 mg administered once daily by subcutaneous injection. Treatment should be started as soon as possible after diagnosis and continued for up to 8 days or until the patient is discharged.
Application route and method

Subcutaneous application

For subcutaneous injection, the abdominal walls should be used alternately. When applying with a pre-filled syringe, the air bubble in the syringe should not be expelled before the injection to prevent loss of the product. The needle should be fully inserted vertically into the skin knuckle held between the thumb and forefinger. Retention of the skin knot should be maintained throughout the injection.

Patients can inject themselves only when the physician decides it is appropriate and with the necessary medical follow-up.

Intravenous administration

Your doctor will determine the dose of your medicine depending on your disease and will apply it to you.
Instructions for self-administration (for subcutaneous administration):

Parts of the ARIXTRA safety syringe:

1. Rigid needle cap

2. Piston cover

3. Piston

4. Handle

5. Safety cover

Syringe - BEFORE USE

2. What are the possible side effects?

Like all medicines, there may be side effects in people who are sensitive to the substances contained in ARIXTRA.
Common side effects (affect at least 1 in 100 people)
bleeding after surgery
accumulation of blood in any part of the body
Seeing blood in the urine
Seeing blood in saliva
bleeding gums
Anemia (decreased red blood cell count)
Edema (accumulation of water in the body)
Uncommon side effects (affect up to 1 in 100 people)
Bleeding (nose bleeding, bleeding in the digestive tract, blood in saliva, blood in urine, blood accumulation in the body)
Edema (accumulation of water in the body)
nausea, vomiting
chest pain
Shortness of breath
skin rash, itching
Decrease or increase in the number of platelets (which allow blood to clot)
Abnormalities in blood platelets
coagulation disorder
Anemia (decreased red blood cell count)
Increase in some chemicals (enzymes) produced in the liver
abnormal liver function tests
Edema (accumulation of water in the body)
Peripheral edema (accumulation of water in the legs)
wound infection
Rare side effects (affect up to 1 in 1000 people)
Leakage from the surgical wound
Allergic reaction (including itching, swelling and rash)
Bleeding in the brain or abdomen
nervousness or confusion
fainting or dizziness, low blood pressure
Dizziness, tiredness, drowsiness, exhaustion
Shortness of breath
Stomach ache
Sudden flushing of the face
Loss of consciousness
Leg or stomach pain
diarrhea or constipation
Increase in bilirubin (a substance produced by the liver) in the blood
Decreased potassium level in the blood
Reaction at the application site
Edema in the genital area